The projected annual revenue for Glaukos is 386MM, an increase of 7.12%. The projected annual non-GAAP EPS is -1.45. IJR - iShares Core S&P Small-Cap ETF holds 3,492K shares representing 6.34% ...
FDA set an Oct. 20, 2025, review deadline for Glaukos' Epioxa NDA, a next-gen corneal cross-linking therapy for keratoconus. Epioxa met primary efficacy goals with favorable safety, supporting its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback